Related Experiment Videos
Yttrium-90 internal radiation therapy for hepatic malignancy.
1Department of Surgery, The University of Illinois at Chicago, 840 S. Wood St. MC 958, Chicago, IL 60612, USA.
Surgical Oncology
|March 11, 2006
Summary
Yttrium-90 (Y(90)) internal radiation therapy offers a safe and potentially survival-extending option for unresectable liver tumors. Further research is needed to define its precise role in managing hepatic malignancy.
Area of Science:
- Hepatobiliary Medicine
- Interventional Radiology
- Oncology
Background:
- Surgical resection is the only potentially curative treatment for hepatic malignancy.
- Many patients with liver tumors are inoperable due to disease stage, liver disease, or comorbidities.
- Locoregional therapies are crucial for managing unresectable hepatic tumors.
Purpose of the Study:
- To review the existing literature on Yttrium-90 (Y(90)) internal radiation therapy.
- To define the current role of Y(90) in the management of hepatic malignancy.
- To assess the safety and survival benefits of Y(90) for liver tumors.
Main Methods:
- Comprehensive literature review of studies on Yttrium-90 (Y(90)) therapy.
- Analysis of data regarding the application of Y(90) in primary and metastatic liver tumors.
- Evaluation of safety profiles and survival outcomes associated with Y(90) treatment.
Main Results:
- Intra-arterial Y(90) has demonstrated safety and potential survival benefits in numerous studies.
- Evidence supports the use of Y(90) for both primary and metastatic liver tumors.
- The exact role of Y(90) in the broader treatment algorithm requires further investigation.
Conclusions:
- Yttrium-90 (Y(90)) is a valuable locoregional therapy for unresectable hepatic tumors.
- Additional data is necessary to fully integrate Y(90) into standard treatment protocols for liver cancer.
- Y(90) represents a significant option in the therapeutic strategies for hepatic malignancy.